Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms.

By F. Tögel, Zhuma Hu, K. Weiss, J. Isaac, C. Lange, C. Westenfelder. AJP - Renal Physiology, 2005

1,186 citations recorded by the source corpus.

Subfields: Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/312533197786d2270b9d5b4c573264d238ff58f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael A. Matthay
2. R. Zemans

In Surgery

1. Michael A. Matthay
2. P. Devarajan

Citations in the corpus

• Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells (2012, positive): “MSCs were shown to demonstrate therapeutic efficacy in animal models of meniscus injury [69], neurological disorders [70], myocardial infarction (MI) [71], lung injury [72], ischemic acute renal failure [73], and others.”
• Update on mechanisms of ischemic acute kidney injury. (2006, background): “Fourth, the mode of protection by exogenously administered MSC may be related not to transdifferentiation processes but rather to powerful anti-inflammatory and antiapoptotic mechanisms that are being uncovered (117,124,125).”
• Exosomes Derived from Mesenchymal Stem Cells (2014, background): “However, this hypothesis has proved to be unreliable by some researchers [20].”
• Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. (2013, background): “Since then, theparacrine effect ofMSCswas observed inmany animalmodels of tissue injury including acutemyocardial infarction [100], reperfusion injury [101], ischemic acute renal failure [102],wound healing [103], skeletal tissue repair [104], acute kidney injury [105] and hypoxic pulmonary vasocons”
• Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung (2009, background): “Recent studies have suggested that bone marrow-derived multipotent mesenchymal stem cells (MSCs) may have therapeutic applications in several clinical disorders including myocardial infarction (17), diabetes (18), sepsis (19), hepatic (20), and acute renal failure (21).”
• Mesenchymal stem cells in health and disease (2008, background): “For example, in a model of acute renal failure, administration of MSCs increased the recovery of renal function through the inhibition of production of pro-inflammatory cytokines, such as IL-1β, TNF and IFNγ, and through an anti-apoptotic effect on target cell”
• Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. (2011, background): “These beneficial effects were shown to be associated with a transient recruitment of MSCs within the kidney with a minimal incorporation in the regenerating tubules [5,40,41].”
• Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. (2007, methodology): “EC and MSC have both been shown to be renoprotective (9, 18, 38).”